A comprehensive view of Takeda Pharmaceutical Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Kao Industrial, Takeda sign Thailand Dengue Prevention and Control memorandum of understanding; collaboration aims to cover all 50 districts in Bangkok and extend to other provinces nationwide to raise awareness about Dengue fever, increase prevention
Published: October 31, 2022 by Kao Corp.
MHRA raises concerns with switching between long-acting J&J, Novartis and Takeda drugs to treat attention-deficit/hyperactivity disorder
Published: October 11, 2022 by Indian Pharma Industry: Policies
Puma Biotechnology to license Japanese drug firm Takeda’s experimental oral drug alisertib used to treat breast and lung cancers in deal worth up to US$294.0M; Puma to be responsible for global development, commercialization of the drug
Published: September 22, 2022 by SeeNews Pharmaceuticals
Takeda’s injectable Takhzyro lanadelumab-flyo now available in US in single-dose prefilled syringes to prevent attacks of hereditary angioedema in adult, pediatric patients 12 years of age and older; HAE affects 1 in 50,000 people worldwide
Published: April 25, 2022 by ENP Newswire
Takeda announces approval in Japan for TAKHZYRO subcutaneous injection for prevention of acute attacks of hereditary angioedema; condition is a rare genetic disorder that causes recurring swelling
Published: March 28, 2022 by Takeda Pharmaceutical Co. Ltd.

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count